extended-release capsule (Adderall XR)
GPTKB entity
Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug formulation
|
| gptkbp:activeIngredient |
gptkb:dextroamphetamine
amphetamine |
| gptkbp:approvedBy |
gptkb:FDA
2001 |
| gptkbp:brand |
Adderall XR
|
| gptkbp:broadcastOn |
gptkb:Schedule_II_controlled_substance
|
| gptkbp:contains |
mixed amphetamine salts
|
| gptkbp:contraindication |
glaucoma
hyperthyroidism history of drug abuse advanced arteriosclerosis known hypersensitivity to amphetamines moderate to severe hypertension symptomatic cardiovascular disease |
| gptkbp:duration |
approximately 12 hours
|
| gptkbp:form |
10 mg
20 mg 5 mg 25 mg 15 mg 30 mg extended-release capsule |
| gptkbp:genericAvailable |
yes
|
| gptkbp:halfLife |
10-13 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
extended-release capsule (Adderall XR)
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:marketedIn |
gptkb:Canada
gptkb:United_States |
| gptkbp:mechanismOfAction |
stimulant
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescribes |
adolescents
adults children |
| gptkbp:riskFactor |
abuse
dependence cardiovascular events growth suppression in children |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
anxiety
headache loss of appetite increased heart rate insomnia dry mouth |
| gptkbp:usedFor |
gptkb:attention_deficit_hyperactivity_disorder
narcolepsy |
| gptkbp:bfsParent |
gptkb:Adderall
|
| gptkbp:bfsLayer |
6
|